Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2025-02-13 Regulatory Filings
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC withdrawing a request for acceleration of the effective date for a registration statement on Form S-1. It is a correspondence related to a regulatory filing process, specifically about a registration statement, not a financial report or announcement of results. The document is short (1100 characters) and does not contain financial data or detailed report content. It is a regulatory communication related to filings but not a report itself. Therefore, it fits best under Regulatory Filings (RNS).
2025-02-13 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about a Virtual Investor segment and a recent approval related to a Phase 2 Study, but it does not contain detailed financial statements or comprehensive financial data. The document is relatively short (5190 characters) and primarily serves as an announcement of an event and includes a press release as an exhibit. There is no indication that this is a full Annual Report, Quarterly Report, or Earnings Release. It is not a certification or officer attestation. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2025-02-11 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by AIM ImmunoTech Inc. It announces that the company will not proceed with an offering until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The document includes a press release as an exhibit and contains forward-looking statements. There are no actual financial statements or detailed financial data included in this filing; it is an announcement of an event related to the company's filings and plans. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2025-02-11 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement Amendment No. 2 filed with the SEC by AIM ImmunoTech Inc. It is a preliminary prospectus for a securities offering, describing the terms of the offering, the securities involved (units, common stock, warrants), the offering price, placement agent details, and compliance with listing standards. The document is clearly related to capital raising and financing activities. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. It is not a proxy, voting results, or governance document. It is a registration statement amendment for a securities offering under the Securities Act of 1933, which fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS. Therefore, the correct classification is Capital/Financing Update (CAP).
2025-02-07 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports an event on February 7, 2025, specifically a press release about a planned follow-up clinical study. The document includes a cautionary statement about forward-looking statements and references an attached press release as Exhibit 99.1. There are no financial statements or detailed financial data included, and the document is relatively short (4904 characters). This type of filing is an announcement of an event or update rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-02-07 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and requests the SEC to declare the Registration Statement effective at a specified date and time. The document is a formal communication related to a securities registration process, not a financial report, earnings release, or other types of filings. It is a regulatory procedural filing related to the registration process, which fits best under Regulatory Filings (RNS). The document length is short (1948 characters), and it is clearly a letter requesting an action rather than a report or announcement of results.
2025-02-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.